Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

Valneva (VALN) announced results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its ...

Partially funded by the Coalition for Epidemic Preparedness Innovations ... of the dose (half dose or full dose) or previous chikungunya infection (CHIKV), and, to a similar extent, to an active ...

Valneva has announced positive outcomes from its Phase III trial of the single-shot IXCHIQ chikungunya virus vaccine in ...

Chikungunya virus (CHIKV ... the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need.

issued a travel notice after identifying higher-than-expected numbers of chikungunya cases in returning travelers 15. An active outbreak was recently declared on the French island La Reunion 16.

today announced positive results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, IXCHIQ ®, in 304 children.

Pune on Monday reported nine suspected cases of GBS, an immunological nerve disorder, taking tally in Maharashtra’s second ...

The health officials said that a new Guillain-Barre Syndrome case was reported in Pune on Tuesday; number of suspected GBS ...

Pune on Monday reported nine suspected cases of Guillain-Barre Syndrome (GBS), an immunological nerve disorder, taking the tally in Maharashtra`s second largest city to 110, officials said, reported ...